Article Text

Cardiac Involvement in Patients With Hematologic Malignancies
  1. Alessandro Allegra, MD,
  2. Andrea Alonci, MD,
  3. Sabina Russo, MD,
  4. Antonino Cannavò, MD,
  5. Giuseppa Penna, MD,
  6. Arianna D'Angelo, MD,
  7. Giacomo Bellomo, MD,
  8. Caterina Musolino, PhD
  1. From the Division of Hematology, University of Messina, Messina, Italy.
  1. Received April 15, 2010, and in revised form June 28, 2010.
  2. Accepted for publication June 28, 2010.
  3. Reprints: Caterina Musolino, PhD, Via Colapesce n.20, 98100, Messina, Italy. E-mail: cmusolino{at}


Authors have reviewed literature about the management of patients with cardiologic disease occurring secondary to hematologic pathology itself or its therapy, with a focus on infiltration of myocardium in acute and chronic leukemia, lymphoma, multiple myeloma, and hypereosinophilic syndrome. Moreover, they evaluated chemotherapy-associated toxicity, particularly for new drugs such as monoclonal antibody therapy, tyrosine kinase inhibitors, arsenic trioxide, bortezomib, and epigenetic therapy. In fact, cardiac toxicity may range from asymptomatic subclinical abnormalities, such as electrocardiographic changes and left ventricular ejection decline, to life-threatening events and lead to chemotherapy dose reduction and delay and, in some cases, for patients with severe side effects, discontinuation of treatment.

Finally, they discussed on the identification of early markers of cardiac injury and on cardiac stem cell therapy as a promising approach to facilitate myocardial regeneration.

Key Words
  • heart failure
  • chemotherapy
  • cardiac neoplasm
  • hematology

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.